The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Synopsis
A cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its long half-life enables it to be administered once daily.
The global Piroxicam market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Piroxicam is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Piroxicam is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Piroxicam in Tendonitis is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Piroxicam include Pfizer, Teva, Mylan, Nostrum, DCPC, FANGMING, JINGHUA, JUMPCAN and Technilab Pharma, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Piroxicam, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Piroxicam.
Report Scope
The Piroxicam market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Piroxicam market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Piroxicam companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Teva
Mylan
Nostrum
DCPC
FANGMING
JINGHUA
JUMPCAN
Technilab Pharma
Apotex Corporation
Keltman Pharmaceuticals
Genpharm
Bayer
PLX Pharma
Chiesi
SK Chemicals
Bioglan Laboratories
APR
CJ HealthCare
SkyePharma
Changzhou Siyao Pharmaceutical
Shanxi Yunpeng Pharmaceutical
Segment by Type
by Dosage Form
Suppositories
Injection
Capsule
Patch
Other
by Route
Oral
Rectal
Segment by Application
Tendonitis
Systemic Traumatic Pain
Musculoskeletal Pain
Contraception
Rheumatoid Arthritis
Chronic Infectious Arthritis
Osteoarthritis
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Piroxicam companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
A cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its long half-life enables it to be administered once daily.
The global Piroxicam market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Piroxicam is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Piroxicam is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Piroxicam in Tendonitis is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Piroxicam include Pfizer, Teva, Mylan, Nostrum, DCPC, FANGMING, JINGHUA, JUMPCAN and Technilab Pharma, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Piroxicam, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Piroxicam.
Report Scope
The Piroxicam market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Piroxicam market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Piroxicam companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Teva
Mylan
Nostrum
DCPC
FANGMING
JINGHUA
JUMPCAN
Technilab Pharma
Apotex Corporation
Keltman Pharmaceuticals
Genpharm
Bayer
PLX Pharma
Chiesi
SK Chemicals
Bioglan Laboratories
APR
CJ HealthCare
SkyePharma
Changzhou Siyao Pharmaceutical
Shanxi Yunpeng Pharmaceutical
Segment by Type
by Dosage Form
Suppositories
Injection
Capsule
Patch
Other
by Route
Oral
Rectal
Segment by Application
Tendonitis
Systemic Traumatic Pain
Musculoskeletal Pain
Contraception
Rheumatoid Arthritis
Chronic Infectious Arthritis
Osteoarthritis
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Piroxicam companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Dosage Form
1.2.1 Global Piroxicam Market Size Growth Rate by Dosage Form: 2019 VS 2023 VS 2030
1.2.2 Suppositories
1.2.3 Injection
1.2.4 Capsule
1.2.5 Patch
1.2.6 Other
1.3 Market by Application
1.3.1 Global Piroxicam Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Tendonitis
1.3.3 Systemic Traumatic Pain
1.3.4 Musculoskeletal Pain
1.3.5 Contraception
1.3.6 Rheumatoid Arthritis
1.3.7 Chronic Infectious Arthritis
1.3.8 Osteoarthritis
1.3.9 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Piroxicam Market Perspective (2019-2030)
2.2 Piroxicam Growth Trends by Region
2.2.1 Global Piroxicam Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Piroxicam Historic Market Size by Region (2019-2024)
2.2.3 Piroxicam Forecasted Market Size by Region (2025-2030)
2.3 Piroxicam Market Dynamics
2.3.1 Piroxicam Industry Trends
2.3.2 Piroxicam Market Drivers
2.3.3 Piroxicam Market Challenges
2.3.4 Piroxicam Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Piroxicam Players by Revenue
3.1.1 Global Top Piroxicam Players by Revenue (2019-2024)
3.1.2 Global Piroxicam Revenue Market Share by Players (2019-2024)
3.2 Global Piroxicam Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Piroxicam Revenue
3.4 Global Piroxicam Market Concentration Ratio
3.4.1 Global Piroxicam Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Piroxicam Revenue in 2023
3.5 Piroxicam Key Players Head office and Area Served
3.6 Key Players Piroxicam Product Solution and Service
3.7 Date of Enter into Piroxicam Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Piroxicam Breakdown Data by Type
4.1 Global Piroxicam Historic Market Size by Type (2019-2024)
4.2 Global Piroxicam Forecasted Market Size by Type (2025-2030)
5 Piroxicam Breakdown Data by Application
5.1 Global Piroxicam Historic Market Size by Application (2019-2024)
5.2 Global Piroxicam Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Piroxicam Market Size (2019-2030)
6.2 North America Piroxicam Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Piroxicam Market Size by Country (2019-2024)
6.4 North America Piroxicam Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Piroxicam Market Size (2019-2030)
7.2 Europe Piroxicam Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Piroxicam Market Size by Country (2019-2024)
7.4 Europe Piroxicam Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Piroxicam Market Size (2019-2030)
8.2 Asia-Pacific Piroxicam Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Piroxicam Market Size by Region (2019-2024)
8.4 Asia-Pacific Piroxicam Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Piroxicam Market Size (2019-2030)
9.2 Latin America Piroxicam Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Piroxicam Market Size by Country (2019-2024)
9.4 Latin America Piroxicam Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Piroxicam Market Size (2019-2030)
10.2 Middle East & Africa Piroxicam Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Piroxicam Market Size by Country (2019-2024)
10.4 Middle East & Africa Piroxicam Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Piroxicam Introduction
11.1.4 Pfizer Revenue in Piroxicam Business (2019-2024)
11.1.5 Pfizer Recent Development
11.2 Teva
11.2.1 Teva Company Detail
11.2.2 Teva Business Overview
11.2.3 Teva Piroxicam Introduction
11.2.4 Teva Revenue in Piroxicam Business (2019-2024)
11.2.5 Teva Recent Development
11.3 Mylan
11.3.1 Mylan Company Detail
11.3.2 Mylan Business Overview
11.3.3 Mylan Piroxicam Introduction
11.3.4 Mylan Revenue in Piroxicam Business (2019-2024)
11.3.5 Mylan Recent Development
11.4 Nostrum
11.4.1 Nostrum Company Detail
11.4.2 Nostrum Business Overview
11.4.3 Nostrum Piroxicam Introduction
11.4.4 Nostrum Revenue in Piroxicam Business (2019-2024)
11.4.5 Nostrum Recent Development
11.5 DCPC
11.5.1 DCPC Company Detail
11.5.2 DCPC Business Overview
11.5.3 DCPC Piroxicam Introduction
11.5.4 DCPC Revenue in Piroxicam Business (2019-2024)
11.5.5 DCPC Recent Development
11.6 FANGMING
11.6.1 FANGMING Company Detail
11.6.2 FANGMING Business Overview
11.6.3 FANGMING Piroxicam Introduction
11.6.4 FANGMING Revenue in Piroxicam Business (2019-2024)
11.6.5 FANGMING Recent Development
11.7 JINGHUA
11.7.1 JINGHUA Company Detail
11.7.2 JINGHUA Business Overview
11.7.3 JINGHUA Piroxicam Introduction
11.7.4 JINGHUA Revenue in Piroxicam Business (2019-2024)
11.7.5 JINGHUA Recent Development
11.8 JUMPCAN
11.8.1 JUMPCAN Company Detail
11.8.2 JUMPCAN Business Overview
11.8.3 JUMPCAN Piroxicam Introduction
11.8.4 JUMPCAN Revenue in Piroxicam Business (2019-2024)
11.8.5 JUMPCAN Recent Development
11.9 Technilab Pharma
11.9.1 Technilab Pharma Company Detail
11.9.2 Technilab Pharma Business Overview
11.9.3 Technilab Pharma Piroxicam Introduction
11.9.4 Technilab Pharma Revenue in Piroxicam Business (2019-2024)
11.9.5 Technilab Pharma Recent Development
11.10 Apotex Corporation
11.10.1 Apotex Corporation Company Detail
11.10.2 Apotex Corporation Business Overview
11.10.3 Apotex Corporation Piroxicam Introduction
11.10.4 Apotex Corporation Revenue in Piroxicam Business (2019-2024)
11.10.5 Apotex Corporation Recent Development
11.11 Keltman Pharmaceuticals
11.11.1 Keltman Pharmaceuticals Company Detail
11.11.2 Keltman Pharmaceuticals Business Overview
11.11.3 Keltman Pharmaceuticals Piroxicam Introduction
11.11.4 Keltman Pharmaceuticals Revenue in Piroxicam Business (2019-2024)
11.11.5 Keltman Pharmaceuticals Recent Development
11.12 Genpharm
11.12.1 Genpharm Company Detail
11.12.2 Genpharm Business Overview
11.12.3 Genpharm Piroxicam Introduction
11.12.4 Genpharm Revenue in Piroxicam Business (2019-2024)
11.12.5 Genpharm Recent Development
11.13 Bayer
11.13.1 Bayer Company Detail
11.13.2 Bayer Business Overview
11.13.3 Bayer Piroxicam Introduction
11.13.4 Bayer Revenue in Piroxicam Business (2019-2024)
11.13.5 Bayer Recent Development
11.14 PLX Pharma
11.14.1 PLX Pharma Company Detail
11.14.2 PLX Pharma Business Overview
11.14.3 PLX Pharma Piroxicam Introduction
11.14.4 PLX Pharma Revenue in Piroxicam Business (2019-2024)
11.14.5 PLX Pharma Recent Development
11.15 Chiesi
11.15.1 Chiesi Company Detail
11.15.2 Chiesi Business Overview
11.15.3 Chiesi Piroxicam Introduction
11.15.4 Chiesi Revenue in Piroxicam Business (2019-2024)
11.15.5 Chiesi Recent Development
11.16 SK Chemicals
11.16.1 SK Chemicals Company Detail
11.16.2 SK Chemicals Business Overview
11.16.3 SK Chemicals Piroxicam Introduction
11.16.4 SK Chemicals Revenue in Piroxicam Business (2019-2024)
11.16.5 SK Chemicals Recent Development
11.17 Bioglan Laboratories
11.17.1 Bioglan Laboratories Company Detail
11.17.2 Bioglan Laboratories Business Overview
11.17.3 Bioglan Laboratories Piroxicam Introduction
11.17.4 Bioglan Laboratories Revenue in Piroxicam Business (2019-2024)
11.17.5 Bioglan Laboratories Recent Development
11.18 APR
11.18.1 APR Company Detail
11.18.2 APR Business Overview
11.18.3 APR Piroxicam Introduction
11.18.4 APR Revenue in Piroxicam Business (2019-2024)
11.18.5 APR Recent Development
11.19 CJ HealthCare
11.19.1 CJ HealthCare Company Detail
11.19.2 CJ HealthCare Business Overview
11.19.3 CJ HealthCare Piroxicam Introduction
11.19.4 CJ HealthCare Revenue in Piroxicam Business (2019-2024)
11.19.5 CJ HealthCare Recent Development
11.20 SkyePharma
11.20.1 SkyePharma Company Detail
11.20.2 SkyePharma Business Overview
11.20.3 SkyePharma Piroxicam Introduction
11.20.4 SkyePharma Revenue in Piroxicam Business (2019-2024)
11.20.5 SkyePharma Recent Development
11.21 Changzhou Siyao Pharmaceutical
11.21.1 Changzhou Siyao Pharmaceutical Company Detail
11.21.2 Changzhou Siyao Pharmaceutical Business Overview
11.21.3 Changzhou Siyao Pharmaceutical Piroxicam Introduction
11.21.4 Changzhou Siyao Pharmaceutical Revenue in Piroxicam Business (2019-2024)
11.21.5 Changzhou Siyao Pharmaceutical Recent Development
11.22 Shanxi Yunpeng Pharmaceutical
11.22.1 Shanxi Yunpeng Pharmaceutical Company Detail
11.22.2 Shanxi Yunpeng Pharmaceutical Business Overview
11.22.3 Shanxi Yunpeng Pharmaceutical Piroxicam Introduction
11.22.4 Shanxi Yunpeng Pharmaceutical Revenue in Piroxicam Business (2019-2024)
11.22.5 Shanxi Yunpeng Pharmaceutical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Piroxicam Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Suppositories
Table 3. Key Players of Injection
Table 4. Key Players of Capsule
Table 5. Key Players of Patch
Table 6. Key Players of Other
Table 7. Global Piroxicam Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 8. Global Piroxicam Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 9. Global Piroxicam Market Size by Region (2019-2024) & (US$ Million)
Table 10. Global Piroxicam Market Share by Region (2019-2024)
Table 11. Global Piroxicam Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 12. Global Piroxicam Market Share by Region (2025-2030)
Table 13. Piroxicam Market Trends
Table 14. Piroxicam Market Drivers
Table 15. Piroxicam Market Challenges
Table 16. Piroxicam Market Restraints
Table 17. Global Piroxicam Revenue by Players (2019-2024) & (US$ Million)
Table 18. Global Piroxicam Market Share by Players (2019-2024)
Table 19. Global Top Piroxicam Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Piroxicam as of 2023)
Table 20. Ranking of Global Top Piroxicam Companies by Revenue (US$ Million) in 2023
Table 21. Global 5 Largest Players Market Share by Piroxicam Revenue (CR5 and HHI) & (2019-2024)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Piroxicam Product Solution and Service
Table 24. Date of Enter into Piroxicam Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Piroxicam Market Size by Type (2019-2024) & (US$ Million)
Table 27. Global Piroxicam Revenue Market Share by Type (2019-2024)
Table 28. Global Piroxicam Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 29. Global Piroxicam Revenue Market Share by Type (2025-2030)
Table 30. Global Piroxicam Market Size by Application (2019-2024) & (US$ Million)
Table 31. Global Piroxicam Revenue Market Share by Application (2019-2024)
Table 32. Global Piroxicam Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 33. Global Piroxicam Revenue Market Share by Application (2025-2030)
Table 34. North America Piroxicam Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 35. North America Piroxicam Market Size by Country (2019-2024) & (US$ Million)
Table 36. North America Piroxicam Market Size by Country (2025-2030) & (US$ Million)
Table 37. Europe Piroxicam Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 38. Europe Piroxicam Market Size by Country (2019-2024) & (US$ Million)
Table 39. Europe Piroxicam Market Size by Country (2025-2030) & (US$ Million)
Table 40. Asia-Pacific Piroxicam Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 41. Asia-Pacific Piroxicam Market Size by Region (2019-2024) & (US$ Million)
Table 42. Asia-Pacific Piroxicam Market Size by Region (2025-2030) & (US$ Million)
Table 43. Latin America Piroxicam Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 44. Latin America Piroxicam Market Size by Country (2019-2024) & (US$ Million)
Table 45. Latin America Piroxicam Market Size by Country (2025-2030) & (US$ Million)
Table 46. Middle East & Africa Piroxicam Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 47. Middle East & Africa Piroxicam Market Size by Country (2019-2024) & (US$ Million)
Table 48. Middle East & Africa Piroxicam Market Size by Country (2025-2030) & (US$ Million)
Table 49. Pfizer Company Detail
Table 50. Pfizer Business Overview
Table 51. Pfizer Piroxicam Product
Table 52. Pfizer Revenue in Piroxicam Business (2019-2024) & (US$ Million)
Table 53. Pfizer Recent Development
Table 54. Teva Company Detail
Table 55. Teva Business Overview
Table 56. Teva Piroxicam Product
Table 57. Teva Revenue in Piroxicam Business (2019-2024) & (US$ Million)
Table 58. Teva Recent Development
Table 59. Mylan Company Detail
Table 60. Mylan Business Overview
Table 61. Mylan Piroxicam Product
Table 62. Mylan Revenue in Piroxicam Business (2019-2024) & (US$ Million)
Table 63. Mylan Recent Development
Table 64. Nostrum Company Detail
Table 65. Nostrum Business Overview
Table 66. Nostrum Piroxicam Product
Table 67. Nostrum Revenue in Piroxicam Business (2019-2024) & (US$ Million)
Table 68. Nostrum Recent Development
Table 69. DCPC Company Detail
Table 70. DCPC Business Overview
Table 71. DCPC Piroxicam Product
Table 72. DCPC Revenue in Piroxicam Business (2019-2024) & (US$ Million)
Table 73. DCPC Recent Development
Table 74. FANGMING Company Detail
Table 75. FANGMING Business Overview
Table 76. FANGMING Piroxicam Product
Table 77. FANGMING Revenue in Piroxicam Business (2019-2024) & (US$ Million)
Table 78. FANGMING Recent Development
Table 79. JINGHUA Company Detail
Table 80. JINGHUA Business Overview
Table 81. JINGHUA Piroxicam Product
Table 82. JINGHUA Revenue in Piroxicam Business (2019-2024) & (US$ Million)
Table 83. JINGHUA Recent Development
Table 84. JUMPCAN Company Detail
Table 85. JUMPCAN Business Overview
Table 86. JUMPCAN Piroxicam Product
Table 87. JUMPCAN Revenue in Piroxicam Business (2019-2024) & (US$ Million)
Table 88. JUMPCAN Recent Development
Table 89. Technilab Pharma Company Detail
Table 90. Technilab Pharma Business Overview
Table 91. Technilab Pharma Piroxicam Product
Table 92. Technilab Pharma Revenue in Piroxicam Business (2019-2024) & (US$ Million)
Table 93. Technilab Pharma Recent Development
Table 94. Apotex Corporation Company Detail
Table 95. Apotex Corporation Business Overview
Table 96. Apotex Corporation Piroxicam Product
Table 97. Apotex Corporation Revenue in Piroxicam Business (2019-2024) & (US$ Million)
Table 98. Apotex Corporation Recent Development
Table 99. Keltman Pharmaceuticals Company Detail
Table 100. Keltman Pharmaceuticals Business Overview
Table 101. Keltman Pharmaceuticals Piroxicam Product
Table 102. Keltman Pharmaceuticals Revenue in Piroxicam Business (2019-2024) & (US$ Million)
Table 103. Keltman Pharmaceuticals Recent Development
Table 104. Genpharm Company Detail
Table 105. Genpharm Business Overview
Table 106. Genpharm Piroxicam Product
Table 107. Genpharm Revenue in Piroxicam Business (2019-2024) & (US$ Million)
Table 108. Genpharm Recent Development
Table 109. Bayer Company Detail
Table 110. Bayer Business Overview
Table 111. Bayer Piroxicam Product
Table 112. Bayer Revenue in Piroxicam Business (2019-2024) & (US$ Million)
Table 113. Bayer Recent Development
Table 114. PLX Pharma Company Detail
Table 115. PLX Pharma Business Overview
Table 116. PLX Pharma Piroxicam Product
Table 117. PLX Pharma Revenue in Piroxicam Business (2019-2024) & (US$ Million)
Table 118. PLX Pharma Recent Development
Table 119. Chiesi Company Detail
Table 120. Chiesi Business Overview
Table 121. Chiesi Piroxicam Product
Table 122. Chiesi Revenue in Piroxicam Business (2019-2024) & (US$ Million)
Table 123. Chiesi Recent Development
Table 124. SK Chemicals Company Detail
Table 125. SK Chemicals Business Overview
Table 126. SK Chemicals Piroxicam Product
Table 127. SK Chemicals Revenue in Piroxicam Business (2019-2024) & (US$ Million)
Table 128. SK Chemicals Recent Development
Table 129. Bioglan Laboratories Company Detail
Table 130. Bioglan Laboratories Business Overview
Table 131. Bioglan Laboratories Piroxicam Product
Table 132. Bioglan Laboratories Revenue in Piroxicam Business (2019-2024) & (US$ Million)
Table 133. Bioglan Laboratories Recent Development
Table 134. APR Company Detail
Table 135. APR Business Overview
Table 136. APR Piroxicam Product
Table 137. APR Revenue in Piroxicam Business (2019-2024) & (US$ Million)
Table 138. APR Recent Development
Table 139. CJ HealthCare Company Detail
Table 140. CJ HealthCare Business Overview
Table 141. CJ HealthCare Piroxicam Product
Table 142. CJ HealthCare Revenue in Piroxicam Business (2019-2024) & (US$ Million)
Table 143. CJ HealthCare Recent Development
Table 144. SkyePharma Company Detail
Table 145. SkyePharma Business Overview
Table 146. SkyePharma Piroxicam Product
Table 147. SkyePharma Revenue in Piroxicam Business (2019-2024) & (US$ Million)
Table 148. SkyePharma Recent Development
Table 149. Changzhou Siyao Pharmaceutical Company Detail
Table 150. Changzhou Siyao Pharmaceutical Business Overview
Table 151. Changzhou Siyao Pharmaceutical Piroxicam Product
Table 152. Changzhou Siyao Pharmaceutical Revenue in Piroxicam Business (2019-2024) & (US$ Million)
Table 153. Changzhou Siyao Pharmaceutical Recent Development
Table 154. Shanxi Yunpeng Pharmaceutical Company Detail
Table 155. Shanxi Yunpeng Pharmaceutical Business Overview
Table 156. Shanxi Yunpeng Pharmaceutical Piroxicam Product
Table 157. Shanxi Yunpeng Pharmaceutical Revenue in Piroxicam Business (2019-2024) & (US$ Million)
Table 158. Shanxi Yunpeng Pharmaceutical Recent Development
Table 159. Research Programs/Design for This Report
Table 160. Key Data Information from Secondary Sources
Table 161. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Piroxicam Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Piroxicam Market Share by Type: 2023 VS 2030
Figure 3. Suppositories Features
Figure 4. Injection Features
Figure 5. Capsule Features
Figure 6. Patch Features
Figure 7. Other Features
Figure 8. Global Piroxicam Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 9. Global Piroxicam Market Share by Application: 2023 VS 2030
Figure 10. Tendonitis Case Studies
Figure 11. Systemic Traumatic Pain Case Studies
Figure 12. Musculoskeletal Pain Case Studies
Figure 13. Contraception Case Studies
Figure 14. Rheumatoid Arthritis Case Studies
Figure 15. Chronic Infectious Arthritis Case Studies
Figure 16. Osteoarthritis Case Studies
Figure 17. Other Case Studies
Figure 18. Piroxicam Report Years Considered
Figure 19. Global Piroxicam Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 20. Global Piroxicam Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 21. Global Piroxicam Market Share by Region: 2023 VS 2030
Figure 22. Global Piroxicam Market Share by Players in 2023
Figure 23. Global Top Piroxicam Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Piroxicam as of 2023)
Figure 24. The Top 10 and 5 Players Market Share by Piroxicam Revenue in 2023
Figure 25. North America Piroxicam Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. North America Piroxicam Market Share by Country (2019-2030)
Figure 27. United States Piroxicam Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Canada Piroxicam Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Europe Piroxicam Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Europe Piroxicam Market Share by Country (2019-2030)
Figure 31. Germany Piroxicam Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. France Piroxicam Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. U.K. Piroxicam Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Italy Piroxicam Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Russia Piroxicam Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Nordic Countries Piroxicam Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Asia-Pacific Piroxicam Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Asia-Pacific Piroxicam Market Share by Region (2019-2030)
Figure 39. China Piroxicam Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Japan Piroxicam Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. South Korea Piroxicam Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Southeast Asia Piroxicam Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. India Piroxicam Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Australia Piroxicam Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Latin America Piroxicam Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Latin America Piroxicam Market Share by Country (2019-2030)
Figure 47. Mexico Piroxicam Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. Brazil Piroxicam Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 49. Middle East & Africa Piroxicam Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 50. Middle East & Africa Piroxicam Market Share by Country (2019-2030)
Figure 51. Turkey Piroxicam Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 52. Saudi Arabia Piroxicam Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 53. Pfizer Revenue Growth Rate in Piroxicam Business (2019-2024)
Figure 54. Teva Revenue Growth Rate in Piroxicam Business (2019-2024)
Figure 55. Mylan Revenue Growth Rate in Piroxicam Business (2019-2024)
Figure 56. Nostrum Revenue Growth Rate in Piroxicam Business (2019-2024)
Figure 57. DCPC Revenue Growth Rate in Piroxicam Business (2019-2024)
Figure 58. FANGMING Revenue Growth Rate in Piroxicam Business (2019-2024)
Figure 59. JINGHUA Revenue Growth Rate in Piroxicam Business (2019-2024)
Figure 60. JUMPCAN Revenue Growth Rate in Piroxicam Business (2019-2024)
Figure 61. Technilab Pharma Revenue Growth Rate in Piroxicam Business (2019-2024)
Figure 62. Apotex Corporation Revenue Growth Rate in Piroxicam Business (2019-2024)
Figure 63. Keltman Pharmaceuticals Revenue Growth Rate in Piroxicam Business (2019-2024)
Figure 64. Genpharm Revenue Growth Rate in Piroxicam Business (2019-2024)
Figure 65. Bayer Revenue Growth Rate in Piroxicam Business (2019-2024)
Figure 66. PLX Pharma Revenue Growth Rate in Piroxicam Business (2019-2024)
Figure 67. Chiesi Revenue Growth Rate in Piroxicam Business (2019-2024)
Figure 68. SK Chemicals Revenue Growth Rate in Piroxicam Business (2019-2024)
Figure 69. Bioglan Laboratories Revenue Growth Rate in Piroxicam Business (2019-2024)
Figure 70. APR Revenue Growth Rate in Piroxicam Business (2019-2024)
Figure 71. CJ HealthCare Revenue Growth Rate in Piroxicam Business (2019-2024)
Figure 72. SkyePharma Revenue Growth Rate in Piroxicam Business (2019-2024)
Figure 73. Changzhou Siyao Pharmaceutical Revenue Growth Rate in Piroxicam Business (2019-2024)
Figure 74. Shanxi Yunpeng Pharmaceutical Revenue Growth Rate in Piroxicam Business (2019-2024)
Figure 75. Bottom-up and Top-down Approaches for This Report
Figure 76. Data Triangulation
Figure 77. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
